Disposition of patients in the 7 subgroup-specific cohorts of the primary and extension studies
| . | Enrolled in primary study (n = 79) . | Enrolled in extension study (n = 35) (%) . | Ongoing (n = 17) (%) . |
|---|---|---|---|
| Idela + R | 32 | 14 (44) | 6 (19) |
| Idela 100 mg | 8 | 3 (38) | 3 (38) |
| Idela 150 mg | 12 | 8 (67) | 1 (8) |
| Delayed Idela 150 mg | 12 | 3 (25) | 2 (17) |
| Idela + B | 33 | 15 (45) | 8 (24) |
| Idela 100 mg | 8 | 1 (13) | 1 (13) |
| Idela 150 mg | 13 | 9 (69) | 6 (46) |
| Delayed Idela 150 mg | 12 | 5 (42) | 1 (8) |
| Idela + BR | |||
| Idela 150 mg | 14 | 6 (43) | 3 (21) |
| . | Enrolled in primary study (n = 79) . | Enrolled in extension study (n = 35) (%) . | Ongoing (n = 17) (%) . |
|---|---|---|---|
| Idela + R | 32 | 14 (44) | 6 (19) |
| Idela 100 mg | 8 | 3 (38) | 3 (38) |
| Idela 150 mg | 12 | 8 (67) | 1 (8) |
| Delayed Idela 150 mg | 12 | 3 (25) | 2 (17) |
| Idela + B | 33 | 15 (45) | 8 (24) |
| Idela 100 mg | 8 | 1 (13) | 1 (13) |
| Idela 150 mg | 13 | 9 (69) | 6 (46) |
| Delayed Idela 150 mg | 12 | 5 (42) | 1 (8) |
| Idela + BR | |||
| Idela 150 mg | 14 | 6 (43) | 3 (21) |
B, bendamustine; Idela, idelalisib; R, rituximab.